Transient Bulk Transfection by Flow Electroporation

CCS Cell Culture Service has established a new technology, which is now offered as a custom service to clients within drug discovery industries. By using the MaxCyte® STX™ Scalable Transfection System CCS is able to transfect batches of up to 10 billion cells in less than 30 minutes. Cell lines, primary cells and stem cells are reproducibly and efficiently transfected while maintaining the integrity of the cells for subsequent assays. As a result, bulk quantities of assay-ready frozen instant cells, which are transiently expressing targets of interest can now be rapidly prepared.

“We are very excited about this technology. Difficult targets or target complexes can now be easily addressed in a high-throughput screening scale by using large quantities of validated transiently transfected cells, even in more in vivo-like cellular backgrounds,” commented Dr Oliver Klotzsche, Managing Director of CCS.

“We are very pleased that CCS has decided to acquire the MaxCyte STX. By providing transient bulk transfection as a custom service, CCS enables everybody to benefit from our technology and helps to get it established as an important tool for drug discovery,” stated Douglas Doerfler, President and CEO at MaxCyte.